Plain-English translation of NCT06310967 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a medication called to see if it can safely and effectively lower uric acid levels in the blood. The study includes people with high uric acid who have normal kidney function, as well as those with advanced kidney disease. Researchers will measure how well the medication works and monitor for any side effects.
Some people have dangerously high levels of uric acid in their blood, which can cause gout, kidney stones, and kidney damage over time. Current treatments don't work well for everyone, especially those with advanced kidney disease, so this trial is exploring whether this new medication could be a better option.
You likely qualify if…
You likely don't qualify if…
If you join, you'll start with a screening visit to confirm you qualify. Then you'll receive either the new medication or a placebo (inactive pill) at increasing doses over several weeks. You'll have a single test dose on day 1, then take the medication twice daily for 4 weeks, with blood and urine samples collected to check how it's working and monitor your safety. The entire study lasts about 5–6 weeks, depending on which group you're in.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
Australia
Taiwan